查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1654141

美國全身麻醉劑市場規模、佔有率、趨勢分析報告：按藥物、給藥途徑、最終用途、應用、國家、細分預測，2025-2030 年

U.S. General Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug, By Route Of Administration, By End-use, By Application, By Country, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 70 Pages | 商品交期: 2-10個工作天內

價格

美國全身麻醉劑市場的成長與趨勢：

根據 Grand View Research, Inc. 的數據，到 2030 年美國全身麻醉劑市場規模預計將達到 20.3 億美元，2025 年至 2030 年期間的複合年成長率為 2.82%。

這種成長主要得益於外科手術數量的增加。美國麻醉師協會 (ASA) 強調，由於人口老化、慢性病盛行率上升以及手術技術的進步，手術量持續增加。美國疾病管制與預防中心在 2024 年 2 月報告稱，約有 1.29 億美國人患有至少一種主要慢性疾病，例如癌症、心臟病、糖尿病或高血壓。慢性病的高發性導致心血管手術和其他手術的數量增加，對有效全身麻醉劑的需求增加。

麻醉技術的進步也是一個重要促進因素。REMIFENTANIL等超短效麻醉劑技術創新可以更好地控制麻醉深度並縮短恢復時間，從而改善患者的治療效果並推動市場成長。此外，包括自動化麻醉輸送系統在內的先進輸送系統和監測技術的發展正在透過提高精度和安全性徹底改變麻醉實踐。

監管發展也扮演重要角色。 FDA 的突破性核准途徑有助於快速獲取新的有效麻醉劑。例如，新型緩釋性麻醉劑ZYNRELEF™ 的最新核准表明，監管方面的進步正在支持創新產品的推出。

美國全身麻醉劑市場報告重點

  • 基於醫藥產品，Propofol部門預計將在 2024 年佔據市場主導地位，收益佔有率達到 25.52%，並且預計在預測期內將以最快的複合年成長率成長。
  • 根據給藥途徑，靜脈注射預計將在 2024 年佔據最大的收益佔有率，預計在預測期內以 3.03% 的複合年成長率成長。
  • 根據應用，膝關節關節重建和髖置換術佔據市場主導地位，佔據了大部分的收益佔有率。
  • 根據最終用途，醫院部門將佔據市場主導地位，到 2024 年將獲得 67.05% 的顯著收益佔有率。醫院是進行大型手術和需要全身麻醉的複雜醫療程序的主要場所。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章美國全身麻醉劑市場變數、趨勢與範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 美國全身麻醉劑市場分析工具
    • 產業分析-波特五力分析
    • PESTEL 分析

第 4 章美國全身麻醉藥物市場：藥物評估與趨勢分析

  • 藥品儀表板
  • 藥物變異分析
  • 按藥物和收益
  • SEVOFLURANE
  • Propofol
  • Dexmedetomidine
  • REMIFENTANIL
  • DESFLURANE
  • 咪達唑侖
  • 其他

第 5 章美國全身麻醉劑市場：給藥途徑估計與趨勢分析

  • 給藥途徑儀表板
  • 給藥途徑變異性分析
  • 按給藥途徑分類的收益
  • 靜脈
  • 吸入

第6章美國全身麻醉劑市場：最終用途估計與趨勢分析

  • 最終用途儀表板
  • 最終用途變化分析
  • 按最終用途分類的收益
  • 醫院
  • 門診手術中心
  • 其他

第7章美國全身麻醉劑市場：應用估計與趨勢分析

  • 應用程式儀表板
  • 使用波動分析
  • 按用途分類的收益
  • 心血管手術
  • 癌症
  • 一般外科
  • 膝關節和髖關節置換術
  • 其他

美國8麻醉劑。

  • 區域控制面板
  • 市場規模、預測趨勢分析，2018 年至 2030 年：
    • 美國

第9章 競爭格局

  • 公司/競爭對手分類
  • 供應商概況
    • 主要經銷商及通路夥伴名單
    • Key company market share analysis, 2024
    • Baxter International Inc.
    • AstraZeneca
    • AbbVie Inc.
    • B. Braun Melsungen AG
    • Fresenius SE &Co. KgaA
    • Pfizer
    • Hospira Inc.
    • Aspen Pharmacare Holdings Limited
    • Hikama Pharmaceuticals plc
    • Abbott Laboratories
Product Code: GVR-4-68040-451-8

U.S. General Anesthesia Drugs Market Growth & Trends:

The U.S. general anesthesia drugs market size is projected to reach USD 2.03 billion by 2030, and is anticipated to grow at a CAGR of 2.82% from 2025 to 2030, according to Grand View Research, Inc. The rising number of surgical procedures primarily drives this growth. The American Society of Anesthesiologists (ASA) highlights a consistent increase in surgeries, attributed to an aging population, the growing prevalence of chronic diseases, and advancements in surgical techniques. The CDC reported in February 2024 that approximately 129 million Americans have at least one major chronic disease, such as cancer, heart disease, diabetes, and hypertension. This high prevalence of chronic conditions necessitates numerous cardiovascular and other surgeries, which in turn drives the demand for effective general anesthesia drugs.

Advancements in anesthesia technology are another critical driver. Innovations such as ultra-short-acting anesthetics, like remifentanil, offer improved control over anesthesia depth and faster recovery times, enhancing patient outcomes and driving market growth. Additionally, the development of advanced delivery systems and monitoring technologies, including automated anesthesia delivery systems, has revolutionized anesthesia practices by improving precision and safety.

Regulatory developments also play a significant role. The FDA's expedited approval pathways for breakthrough therapies facilitate quicker access to new and effective anesthetics. For instance, the recent approval of ZYNRELEFTM, a novel extended-release anesthetic, illustrates how regulatory advancements support the introduction of innovative products.

U.S. General Anesthesia Drugs Market Report Highlights:

  • Based on drug, the propofol segment dominated the market with a substantial revenue share of 25.52% in 2024 and is also expected to grow at the fastest CAGR during the forecast period, driven by its widespread use as a preferred agent for induction and maintenance of general anesthesia.
  • Based on route of administration, the intravenous segment held the largest revenue share in 2024 and is also expected to grow at the fastest CAGR of 3.03% during the forecast period
  • Based on application, the knee and hip replacements segment dominated the market, capturing a substantial revenue share.
  • Based on end-use, the hospitals segment dominated the market, capturing a substantial revenue share of 67.05% in 2024. Hospitals are the primary settings for major surgeries and complex medical procedures that require general anesthesia.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Route of Administration
    • 1.2.3. End Use
    • 1.2.4. Application
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Outlook
    • 2.2.2. Route of Administration
    • 2.2.3. End Use
    • 2.2.4. Application
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. General Anesthesia Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Volume Of Surgical Procedures
      • 3.2.1.2. Advancements In Anesthesia Technology
      • 3.2.1.3. Regulatory Developments
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Regulatory and Compliance Challenges
      • 3.2.2.2. Adverse Effects and Safety Concerns
  • 3.3. U.S. General Anesthesia Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. General Anesthesia Drugs Market: Drug Estimates & Trend Analysis

  • 4.1. U.S. General Anesthesia Drugs Market: Drug Dashboard
  • 4.2. U.S. General Anesthesia Drugs Market: Drug Movement Analysis
  • 4.3. U.S. General Anesthesia Drugs Market by Drug, Revenue
  • 4.4. Sevoflurane
    • 4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Propofol
    • 4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Dexmedetomidine
    • 4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Remifentanil
    • 4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Desflurane
    • 4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Midazolam
    • 4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. General Anesthesia Drugs Market: Route of Administration Estimates & Trend Analysis

  • 5.1. U.S. General Anesthesia Drugs Market: Route of Administration Dashboard
  • 5.2. U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
  • 5.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 5.4. Intravenous
    • 5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Inhaled
    • 5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. General Anesthesia Drugs Market: End Use Estimates & Trend Analysis

  • 6.1. U.S. General Anesthesia Drugs Market: End Use Dashboard
  • 6.2. U.S. General Anesthesia Drugs Market: End Use Movement Analysis
  • 6.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Ambulatory Surgical Centers
    • 6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. General Anesthesia Drugs Market: Application Estimates & Trend Analysis

  • 7.1. U.S. General Anesthesia Drugs Market: Application Dashboard
  • 7.2. U.S. General Anesthesia Drugs Market: Application Movement Analysis
  • 7.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
  • 7.4. Heart Surgeries
    • 7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Cancer
    • 7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. General Surgery
    • 7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Knee and hip replacements
    • 7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Other
    • 7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. General Anesthesia Drugs Market: Regional Estimates & Trend Analysis by Drug, Route of Administration, End Use and Application

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
    • 8.2.1. U.S.
      • 8.2.1.1. Key country dynamics
      • 8.2.1.2. Regulatory framework/ reimbursement structure
      • 8.2.1.3. Competitive scenario
      • 8.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Vendor Landscape
    • 9.2.1. List of key distributors and channel partners
    • 9.2.2. Key company market share analysis, 2024
    • 9.2.3. Baxter International Inc.
      • 9.2.3.1. Company overview
      • 9.2.3.2. Financial performance
      • 9.2.3.3. Drug benchmarking
      • 9.2.3.4. Strategic initiatives
    • 9.2.4. AstraZeneca
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Drug benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. AbbVie Inc.
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Drug benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. B. Braun Melsungen AG
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Drug benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. Fresenius SE & Co. KgaA
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Drug benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Pfizer
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Drug benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Hospira Inc.
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Drug benchmarking
      • 9.2.9.4. Strategic initiatives
    • 9.2.10. Aspen Pharmacare Holdings Limited
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Drug benchmarking
      • 9.2.10.4. Strategic initiatives
    • 9.2.11. Hikama Pharmaceuticals plc
      • 9.2.11.1. Company overview
      • 9.2.11.2. Financial performance
      • 9.2.11.3. Drug benchmarking
      • 9.2.11.4. Strategic initiatives
    • 9.2.12. Abbott Laboratories
      • 9.2.12.1. Company overview
      • 9.2.12.2. Financial performance
      • 9.2.12.3. Drug benchmarking
      • 9.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List Of Abbreviation
  • Table 2 U.S. General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 3 U.S. General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 4 U.S. General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 5 U.S. General Anesthesia Drugs Market, Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. General Anesthesia Drugs Market: Market Outlook
  • Fig. 10 Colorectal Surgery Competitive Insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 U.S. General Anesthesia Drugs Market Driver Impact
  • Fig. 14 U.S. General Anesthesia Drugs Market Restraint Impact
  • Fig. 15 U.S. General Anesthesia Drugs Market Strategic Initiatives Analysis
  • Fig. 16 U.S. General Anesthesia Drugs Market: Drug Movement Analysis
  • Fig. 17 U.S. General Anesthesia Drugs Market: Drug Outlook And Key Takeaways
  • Fig. 18 Sevoflurane market estimates and forecast, 2018 - 2030
  • Fig. 19 Propofol market estimates and forecast, 2018 - 2030
  • Fig. 20 Dexmedetomidine market estimates and forecast, 2018 - 2030
  • Fig. 21 Remifentanil market estimates and forecast, 2018 - 2030
  • Fig. 22 Desflurane market estimates and forecast, 2018 - 2030
  • Fig. 23 Midazolam market estimates and forecast, 2018 - 2030
  • Fig. 24 Others market estimates and forecast, 2018 - 2030
  • Fig. 25 U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
  • Fig. 26 U.S. General Anesthesia Drugs Market: Route of Administration Outlook And Key Takeaways
  • Fig. 27 Intravenous market estimates and forecast, 2018 - 2030
  • Fig. 28 Inhaled market estimates and forecast, 2018 - 2030
  • Fig. 29 U.S. General Anesthesia Drugs Market: End Use Movement Analysis
  • Fig. 30 U.S. General Anesthesia Drugs Market: End Use Outlook And Key Takeaways
  • Fig. 31 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 32 Ambulatory Surgical Centers market estimates and forecast, 2018 - 2030
  • Fig. 33 Others market estimates and forecast, 2018 - 2030
  • Fig. 34 U.S. General Anesthesia Drugs Market: Application Movement Analysis
  • Fig. 35 U.S. General Anesthesia Drugs Market: Application Outlook And Key Takeaways
  • Fig. 36 Heart Surgeries market estimates and forecast, 2018 - 2030
  • Fig. 37 Cancer market estimates and forecast, 2018 - 2030
  • Fig. 38 General Surgery market estimates and forecast, 2018 - 2030
  • Fig. 39 Knee and hip replacements market estimates and forecast, 2018 - 2030
  • Fig. 40 Other market estimates and forecast, 2018 - 2030
  • Fig. 41 Market share of key market players- U.S. General Anesthesia Drugs Market